Is Syrup Citralka Safe in Breastfeeding Mothers?
Disodium hydrogen citrate syrup (Citralka) is likely safe for use in breastfeeding mothers, as citrate salts are naturally occurring compounds in the body with minimal transfer to breast milk and no known adverse effects on nursing infants.
Rationale for Safety
The available FDA drug label information for Citralka 1 does not contain specific contraindications for breastfeeding, and the warnings listed pertain only to external use formulations (which appears to be a labeling error in the database, as Citralka is an oral urinary alkalinizer). The actual product—disodium hydrogen citrate—is a citrate salt used to alkalinize urine and manage urinary tract conditions.
Key Safety Considerations:
Minimal systemic absorption and milk transfer: Citrate is a naturally occurring compound in human metabolism (part of the Krebs cycle) and is present in breast milk at baseline physiological levels. Oral citrate supplementation primarily acts locally in the urinary tract and has limited systemic effects that would transfer to breast milk in clinically significant amounts.
No documented adverse effects: There are no case reports or studies documenting harm to breastfed infants from maternal use of citrate-based urinary alkalinizers 2, 3.
General medication safety principles: Most medications transfer into breast milk in amounts that are subclinical and do not exert pharmacological activity in the infant 2, 3. The dose transferred is typically well below therapeutic levels.
Clinical Approach
When prescribing Citralka to a breastfeeding mother:
Confirm the indication: Ensure the medication is necessary for maternal health (e.g., urinary stone prevention, urinary tract infection management, metabolic acidosis)
Use standard dosing: No dose adjustment is needed for breastfeeding mothers
Monitor the infant for:
- Normal feeding patterns
- Normal stool consistency (citrate salts can have mild laxative effects if absorbed systemically in large amounts, though this is unlikely)
- Normal behavior and alertness
Counsel the mother: Explain that the medication is considered safe, and she should continue breastfeeding without interruption
Important Caveats
Avoid excessive caution: Healthcare providers often refuse needed treatment to breastfeeding women based on outdated or overly cautious product information rather than evidence-based assessment 4. This can lead to adverse outcomes for both mother and infant.
Untreated maternal conditions pose greater risk: The risk of untreated urinary tract conditions (infection, stone formation, metabolic disturbances) to maternal health typically outweighs theoretical minimal infant exposure to citrate salts 5.
Reliable information sources: Product information often does not reflect evidence-based studies and is rarely updated 4. For current information, consult LactMed (Drugs and Lactation Database) or similar evidence-based resources 2, 6.
The benefits of treating the mother's urinary condition with Citralka clearly outweigh any theoretical minimal risk to the breastfed infant, and breastfeeding should continue without interruption.